GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed price. Currency in GBp
1,507.60
-1.60 (-0.11%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous close1,509.20
Open1,501.00
Bid1,500.00 x 175400
Ask1,520.00 x 417900
Day's range1,501.00 - 1,519.80
52-week range1,236.40 - 1,724.50
Volume8,137,419
Avg. volume9,551,702
Market cap74.067B
Beta1.03
PE ratio (TTM)48.63
EPS (TTM)31.00
Earnings date25 Jul 2018
Forward dividend & yield0.80 (5.60%)
Ex-dividend dateN/A
1y target est1,540.22
  • Why the world needs more than one Ebola vaccine
    Reuters7 hours ago

    Why the world needs more than one Ebola vaccine

    LONDON (Reuters) - - In the life-and-death race to make the first effective vaccine against Ebola, one company - Merck (MRK.N) - seems bound to win. Immunisations with Merck's VSV EBOV experimental shot began in Congo this week - a big moment in a 40-year fight against a disease that until now could only be tackled by isolation and strict hygiene. Having this vaccine means the world is better placed now than it was in 2014-2016, when the haemorrhagic fever killed more than 11,300 people in history's worst Ebola outbreak in West Africa.

  • MarketWatch11 hours ago

    Merck’s experimental and unlicensed Ebola vaccine is being used in latest outbreak

    The World Health Organization has started to vaccinate thousands of people considered at high risk of contacting the infectious and often-deadly disease Ebola in the Democratic Republic of Congo. The WHO said Monday it is working with NGOs and community leaders to administer an experimental vaccine that was studied in a trial in Guinea in 2015, but has not yet been used to contain a major outbreak. Most are in a remote town, but there are four confirmed cases in Mbandaka, the provincial capital which has a population of more than 1 million people.

  • The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive
    Zacks11 hours ago

    The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive

    The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive

  • Top Stock Reports for Cisco, Kraft Heinz & Sinopec
    Zacksyesterday

    Top Stock Reports for Cisco, Kraft Heinz & Sinopec

    Top Stock Reports for Cisco, Kraft Heinz & Sinopec

  • Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval
    Zacksyesterday

    Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval

    Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

  • Business Wire2 days ago

    ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV

    ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Comm

  • Business Wire2 days ago

    ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV

    LONDON--(BUSINESSWIRE)-- Juluca maintains viral suppression with two drugs in the smallest single pill regimen ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with ...

  • Regulators flag possible birth defect link to GSK's HIV drug
    Reuters5 days ago

    Regulators flag possible birth defect link to GSK's HIV drug

    U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's (GSK.L) HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years. Friday's move by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) follows preliminary data from a study in Botswana which found four cases of neural tube defects in babies born to mothers who became pregnant while taking the drug.

  • Reuters - UK Focus5 days ago

    Regulators flag possible birth defect link to GSK's HIV drug

    U.S. and European regulators said they were assessing evidence that GlaxoSmithKline (Other OTC: GLAXF - news) 's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years. Friday's move by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) follows preliminary data from a study in Botswana which found four cases of neural tube defects in babies born to mothers who became pregnant while taking the drug.

  • Reuters - UK Focus6 days ago

    Hikma reaffirms full-year revenue forecast, cites better generics business

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) on Friday reaffirmed its revenue guidance for the full year, noting its generics business was performing better due to a favourable product mix, despite continued pricing pressure in the United (Shenzhen: 000925.SZ - news) States. The drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million and $600 million in 2018. Sigurdur Olafsson, former generics chief at drug giant Teva Pharmaceuticals, was named Hikma's chief executive officer in February.

  • GSK bets on lift from new lung drugs ahead of Advair's last gasp
    Reuters6 days ago

    GSK bets on lift from new lung drugs ahead of Advair's last gasp

    GlaxoSmithKline (GSK.L) is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend. The British drugmaker has dominated the lung drug market for decades, but its pre-eminence is no longer guaranteed, given declining sales of the ageing Advair inhaler, which could soon face generic competition in the United States. The market is also seeing intensified pricing pressure, raising doubts over the long-term profitability of newer drugs.

  • Reuters - UK Focus6 days ago

    GSK bets on lift from new lung drugs ahead of Advair's last gasp

    GlaxoSmithKline (Other OTC: GLAXF - news) is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend. The British drugmaker has dominated the lung drug market for decades, but its pre-eminence is no longer guaranteed, given declining sales of the ageing Advair inhaler, which could soon face generic competition in the United States. The market is also seeing intensified pricing pressure, raising doubts over the long-term profitability of newer drugs.

  • Glaxo Cuts Jobs in Finance, Adds Ones in Cancer in Hunt for Drugs
    Bloomberg6 days ago

    Glaxo Cuts Jobs in Finance, Adds Ones in Cancer in Hunt for Drugs

    GlaxoSmithKline Plc is cutting finance and accounting positions while bringing in people with cancer and science backgrounds as the U.K.’s biggest drug company shifts spending to develop its best new treatments. The new strategy has led to a “reasonable number” of job cuts, said Luke Miels, president of the London-based company’s global pharmaceutical division, declining to quantify them. Glaxo at the same time is increasing the number of medical science liaisons, specialists who establish relationships with top doctors, as well other roles, he said in an interview.

  • Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal
    Reuters6 days ago

    Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

    For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion (46 billion pound) deal last week to buy drugmaker Shire (SHP.L) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor.

  • Reuters - UK Focus6 days ago

    FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal

    For Christophe Weber, the boss of Japan's Takeda Pharmaceutical, securing a $62 billion deal last week to buy drugmaker Shire (Xetra: S7E.DE - news) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor. When you combine two pipelines you can be more stringent," he said in London, where he is meeting investors and analysts.

  • MPs call for post-Brexit pharmaceutical deal with EU
    Reuters7 days ago

    MPs call for post-Brexit pharmaceutical deal with EU

    Britain must make a continued form of membership of the European Medicines Agency (EMA) a priority to protect the pharmaceutical industry and patients after Brexit, MPs said. The highly regulated industry fears disruption as the EMA relocates from London to Amsterdam, creating uncertainty about drug approvals after 2019. The EMA is already reallocating regulatory work done by experts in Britain to other countries.

  • Reuters - UK Focus7 days ago

    UK lawmakers call for post-Brexit pharmaceutical deal with EU

    Britain must make a continued form of membership of the European Medicines Agency (EMA) a priority to protect the pharmaceutical industry and patients after Brexit, UK lawmakers said. The highly regulated industry fears disruption as the EMA relocates from London to Amsterdam, creating uncertainty about drug approvals after 2019. The EMA is already reallocating regulatory work done by experts in Britain to other countries.

  • AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study
    Zacks9 days ago

    AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

    AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.

  • Reuters14 days ago

    Drugmaker GSK rings in more change as CFO heads for exit in 2019

    GlaxoSmithKline Plc, Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year. The former Goldman Sachs investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday. Dingemans' departure provides a further opportunity for Chief Executive Emma Walmsley to stamp her imprint on the group as she tries to boost sales and improve productivity in the core pharmaceuticals division.

  • Reuters - UK Focus14 days ago

    Drugmaker GSK rings in more change as CFO heads for exit in 2019

    GlaxoSmithKline Plc (Other OTC: GLAXF - news) , Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year. The former Goldman Sachs (NYSE: GS-PB - news) investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday. Dingemans' departure provides a further opportunity for Chief Executive Emma Walmsley to stamp her imprint on the group as she tries to boost sales and improve productivity in the core pharmaceuticals division.

  • Reuters14 days ago

    Drugmaker GSK rings in more change as CFO heads for exit in 2019

    GlaxoSmithKline Plc (GSK.L), Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year. The former Goldman Sachs (GS.N) investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday. Dingemans' departure provides a further opportunity for Chief Executive Emma Walmsley to stamp her imprint on the group as she tries to boost sales and improve productivity in the core pharmaceuticals division.

  • Reuters - UK Focus14 days ago

    GlaxoSmithKline CFO Dingemans to retire in 2019

    GlaxoSmithKline Plc chief financial officer Simon Dingemans has decided to retire, the company said on Wednesday. Dingemans will step down from the board in May 2019, the company said in a statement. The ...

  • Forbes17 days ago

    Follow These Dividend Leaders For 5% To 12% Yields Plus Upside

    From utilities to REITs (real estate investment trusts) to high yield bonds, many are getting crushed as rates rise. All pay 5% to 12% dividends and have additional price upside to boot. GlaxoSmithKline is a U.K.-based pharmaceutical stock that has earned a place among healthcare’s blue-chip elite.

  • Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View
    Zacks19 days ago

    Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View

    Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.

  • Bloomberg20 days ago

    Glaxo's Advair Is the $100 Billion Asthma Drug That Won't Die

    Sharon Bassett tries to stretch a month’s supply of GlaxoSmithKline Plc’s Advair over 60 days to save money on the asthma treatment because the U.S. lacks a cheaper generic version. Since 2001, Advair has helped children and adults with chronic lung diseases while raking in about $100 billion in sales for Glaxo along the way. “It’s been a particularly long and frustrating journey,” said Steve Miller, chief medical officer of Express Scripts Holding Co., which negotiates drug prices for employers and insurers.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes